Introgen Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Introgen Therapeutics, Inc.
P&G appeals a decision advising it to discontinue a ‘#1’ claim on packaging and ads for Oral-B Precision Clean Interdental Picks because the context and font suggest they are tops in their categories, rather than the intended message of being sold by the marketer of the most recommended flossing brand.
Verily Life Sciences and iRhythm Technologies have agreed to co-develop technology for screening, diagnosing and managing patients with atrial fibrillation, combining iRhythm’s artificial intelligence system for diagnosing arrhythmias with Verily’s health data analytics technology.
Health And Wellness On Capitol Hill: Monograph Reform, Wyden On CBD Rule, OTC Daily Contraceptive Access
Energy and Commerce members try again on monograph; Democrats want to ensure OTC oral contraceptive access; Wyden asks for faster CBD rulemaking at FDA; and House passes FDA's FY 2020 funding.
Legal dispute between FDA and Pharmanex decided in 1999 could be precedent for using hemp-derived ingredients including CBD in supplements, even though CBD already has been authorized for clinical drug evaluation and for use in a drug, says attorney Miriam Guggenheim.
- Other Names / Subsidiaries
- Gendux Molecular Limited